Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2017 12:03 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology

PHILADELPHIA, May 31, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it continues to bolster its scientific capabilities by...
May 31, 2017 11:38 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities

PHILADELPHIA, May 31, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it continues to build its manufacturing and scientific...
May 15, 2017 17:23 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017

PHILADELPHIA, May 15, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2017. The net loss was approximately...
March 31, 2017 18:19 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016

Hemispherx Biopharma Management Team Continues Its Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value Conference Call...
March 06, 2017 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017

PHILADELPHIA, March 06, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it has met a major milestone, the commencement of...
February 02, 2017 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. Announces $1 Million Registered Direct Offering

PHILADELPHIA, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”), announced today that it has entered into definitive agreements with several...
January 26, 2017 10:51 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in Europe

PHILADELPHIA, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that an order of newly manufactured rintatolimod (Ampligen®) for sale utilizing the Early Access...
January 11, 2017 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients

PHILADELPHIA, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the "Company") announced today that the rintatolimod European early access program (EAP) designed...
November 21, 2016 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma to Present at the 9th Annual LD Micro Main Event

PHILADELPHIA, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the "Company") announced today that it will be presenting at the 9th annual LD Micro Main Event...
November 14, 2016 16:36 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ended September 30, 2016

PHILADELPHIA, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announces the filing of its Quarterly Report and its financial results for the nine months ended September 30, 2016....